Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders held by Spero Therapeutics, Inc. on October 27, 2020. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market under the symbol SPRO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
A quorum of 17,853,783 shares (68.75% of outstanding shares) was present at the meeting. The following actions were taken:
- Director Elections: Three Class III directors were reelected to serve until the 2023 annual meeting:
- Milind Deshpande, Ph.D. (8,303,201 votes for; 1,341,441 withheld)
- Jean-François Formela, M.D. (8,304,029 votes for; 1,340,613 withheld)
- Ankit Mahadevia, M.D. (8,933,743 votes for; 710,899 withheld)
- Accounting Firm Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2020 (17,675,631 votes for; 163,741 against; 14,411 abstained).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares eligible to vote (25,970,105) and the quorum threshold met (68.75%).
- Confirm the re-election of the Class III directors and the specific vote counts for each nominee.
- Validate the ratification of PricewaterhouseCoopers LLP as the auditor for the 2020 fiscal year.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.